https://www.selleckchem.com/pr....oducts/gsk2193874.ht
myeloid cells. Advanced age of the patients, comorbidities, immunosuppressive bone marrow microenvironment, and cytokine release syndrome are some other challenges that are not unique to myeloid malignancies but pose significant challenge for the successful adaptation of this approach for treatment. In this review, we highlight the challenges and solutions to adopt chimeric antigen receptor T-cell therapies to treat myeloid malignancies. Immune checkpoint inhibition has vastly improved the treatment of solid tumors, but most patients
Like
Comment
Share
